[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-351671-105":59,"doc-detail-351671-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","mdm2-inhibition-with-alrizomadlin-apg-115-in-tp53-wild-type-salivary-gland-cancers-a-phase-i-clinical-trial","MDM2 Inhibition with Alrizomadlin (APG-115) in TP53 wild-type salivary gland cancers - a phase I clinical trial","","MDM2 inhibitors were studied preclinically for adenoid cystic carcinoma, but clinical trials were limited. This phase I trial (NCT03781986) evaluated safety and antitumor activity of oral alrizomadlin (APG-115), with or without carboplatin, in TP53 wild-type unresectable recurrent/metastatic salivary gland cancers, with planned 1:1 randomization. Dose-limiting toxicity and response rate were co-primary; secondary endpoints included safety, survival, and response by histology. After early combination toxicity, patients moved to alrizomadlin monotherapy, showing encouraging tolerability and a reported response rate with median PFS of 10.5 months, particularly in TP53 wild-type salivary gland cancers including ACC.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/mdm2-inhibition-with-alrizomadlin-apg-115-in-tp53-wild-type-salivary-gland-cancers-a-phase-i-clinical-trial/351671/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/mdm2-inhibition-with-alrizomadlin-apg-115-in-tp53-wild-type-salivary-gland-cancers-a-phase-i-clinical-trial/351671.png","ImageObject",300,407,{"name":92,"@type":93},"Cart","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-29","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":19},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What was the purpose of this phase I trial?","Question",{"text":112,"@type":113},"The trial assessed the safety and antitumor activity of oral alrizomadlin (APG-115), with or without carboplatin, in TP53 wild-type unresectable recurrent or metastatic salivary gland cancers.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Why was the study modified from combination therapy to monotherapy?",{"text":117,"@type":113},"After enrollment of 4 patients on combination therapy, the trial was modified to a single-arm alrizomadlin monotherapy due to excess toxicity.",{"name":119,"@type":110,"acceptedAnswer":120},"What were the primary and key secondary endpoints?",{"text":121,"@type":113},"Primary endpoints were dose-limiting toxicity (DLT) and response rate (RR) for alrizomadlin monotherapy with or without carboplatin. Secondary endpoints included safety, survival, and RR by tumor histology.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},351671,1790409198,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":19,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":52,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},18829141979164,"https://eur-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","Article [https://doi.org/10.1038/s41467-026-70653-3](https://doi.org/10.1038/s41467-026-70653-3)  \nMDM2 Inhibition with Alrizomadlin (APG- 115) in TP53 wild-type salivary gland cancers:  \na phase I clinical trial  \nReceived: 26 September 2025  \n\n| Accepted: 2 March 2026 |\n| --- |\n| |\n| Check for updates |\n\nAlexander T. Pearson 1,2,6, Jameel Muzaffar3,6, Kedar Kirtane3,6, Emily Bellile4, Krithika Suresh 4, Ari J. Rosenberg 1, Francis Worden4, Christine H. Chung 3, Everett Vokes1, J. Chad Brenner 4, Apurva Bhangale 4, Jon McHugh4, Kristy Warner4, Felipe Nor4, Jacques E. Nor4, Keri Innes4, Yifan Zhai5, Tommy Fu5 & Paul L. Swiecicki 4,6   \nPreclinical studies have evaluated murine double minue 2 (MDM2) inhibitors as a treatment for adenoid cystic carcinoma (ACC), but clinical trials are lacking. This phase I trial (NCT03781986) assesses the safety and antitumor activity of an oral MDM2 inhibitor, alrizomadlin (APG-115), +/ -carboplatin in TP53 wild type unresectable recurrent/metastatic salivary gland cancers (R/MSGC) with a planned 1:1 randomization to carboplatin chemotherapy. The coprimary endpoints are determination of dose-limiting toxicity (DLT) and response rate (RR) for alrizomadlin monotherapy +/-carboplatin. Secondary endpoints include safety, survival, and RR by tumor histology. After enrollment of 4 patients to combination therapy, the trial was modiﬁed to a single arm study of alrizomadlin monotherapy due to excess toxicity. 1 DLT was seen in the combination arm, all patients had ≥ G3 treatment related adverse events (TRAE). 37 patients were enrolled to alrizomadlin monotherapy. 3 DLTs were encountered, 67% of patients had ≥ G3 TRAE. The RR was 15% with median progression free survival 10.5 months. These ﬁndings demonstrate encouraging tolerability of alrizomadlin monotherapy with antitumor activity inpatients with TP53 wild type SGC, especially ACC.  \nMalignant salivary gland cancers (SGC) are a rare site of head and neck tumors accounting for ~6–8% of primary head and neck cancers1. Most patients present with localized disease and are treated with curative intent; however, a subset of patients develop metastatic disease. Once metastatic, treatment is palliative, and disease behavior is variable in so far as some patients have asymptomatic, indolent disease for years before growing rapidly and necessitating treatment. Results of historical trials in metastatic SGC are difﬁcult to interpret given inclusion of patient with indolent disease. As such, contemporary studies have limited enrollment to patients with documented progressive disease2.  \nAlthough often grouped together due to their rarity and anatomic location, malignant metastatic SGC encompass several distinct tumors of which the most common is adenoid cystic carcinoma (ACC)3.  \nThere are no approved systemic therapeutics for ACC. Cytotoxic chemotherapies and combinations have shown overall response rate (ORR) ranging 0-44%(albeit with unclear survival beneﬁt)4, and multireceptor vascular endothelilal growth receptor (VEGFR) tyrosine kinase inhibitors which have shown response rates ranging from 0-15% and a median progression free survival (PFS) of 5.7–17.5 months (mo)5–10. In a randomized trial, axitinib demonstrated an  \n1University of Chicago Cancer Center, Chicago, IL, USA. 2Chan Zuckerberg Biohub Chicago, Chicago, IL, USA. 3H. Lee Mofﬁtt Cancer Center and Research Institute, Tampa, FL, USA. 4University of Michigan Rogel Cancer Center, Ann Arbor, MI, USA. 5Ascentage Pharma, Rockville, MD, USA. 6These authors contributed equally: Alexander T. Pearson, Jameel Muzaffar, Kedar Kirtane, Paul L. Swiecicki. e-mail: [pswiecic@med.umich.edu](pswiecic@med.umich.edu)  \nimprovement in mPFS (5.7 vs 2.8 mo) versus observation with an ORR of only 9%5.  \nOther non-ACC salivary gland cancers include salivary ductal carcinoma, acinic cell carcinoma, mucoepidermoid carcinoma, and mammary analog secretory carcinoma. Although some of these tumors may have targetable molecular ","cbCaid5VYLStXWM8","https://ap.wps.com/l/cbCaid5VYLStXWM8","pdf",1149263,"English","# Results\n## Patient and disease characteristics\n## Endpoints and safety\n## Dose-limiting toxicity and response rate\n## Progression-free survival","[{\"question\":\"What was the purpose of this phase I trial?\",\"answer\":\"The trial assessed the safety and antitumor activity of oral alrizomadlin (APG-115), with or without carboplatin, in TP53 wild-type unresectable recurrent or metastatic salivary gland cancers.\"},{\"question\":\"Why was the study modified from combination therapy to monotherapy?\",\"answer\":\"After enrollment of 4 patients on combination therapy, the trial was modified to a single-arm alrizomadlin monotherapy due to excess toxicity.\"},{\"question\":\"What were the primary and key secondary endpoints?\",\"answer\":\"Primary endpoints were dose-limiting toxicity (DLT) and response rate (RR) for alrizomadlin monotherapy with or without carboplatin. Secondary endpoints included safety, survival, and RR by tumor histology.\"}]","MDM2 Inhibition with Alrizomadlin (APG-115) in TP53 wild-type salivary gland cancers - a phase I clinical trial | PDF",1790095207,25,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/293a9effc7f0116035e2333e2e115f00.webp",983,1305,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1e0b0061b3cf6b82d45c06ed601530bb.webp",982,1304,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/42adc2034228512c4f0bce74500adcf2.webp",981,1303,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3a3f5e923be9d73660e7241a5769f173.webp",980,1301]